Chandra Bhagat Pharma Ltd vs Infinium Pharmachem Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Chandra Bhagat Pharma Ltd is ₹ 33 as of 27 Apr 15:30 . The P/E Ratio of Chandra Bhagat Pharma Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Infinium Pharmachem Ltd changed from 28.2 on March 2024 to 46.3 on March 2025 . This represents a CAGR of 28.13% over 2 years The Market Cap of Chandra Bhagat Pharma Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Infinium Pharmachem Ltd changed from ₹ 318.68 crore on March 2024 to ₹ 376.96 crore on March 2025 . This represents a CAGR of 8.76% over 2 years The Dividend Payout of Chandra Bhagat Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Infinium Pharmachem Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Chandra Bhagat Pharma Ltd

Chandra Bhagat Pharma Limited was incorporated as a Private Limited Company with the name 'Chandra Bhagat Pharma Private Limited' at Mumbai on March 10, 2003.
Consequent upon the conversion of the Company from Private Limited Company to Public Limited Company, the name of the Company was changed to 'Chandra Bhagat Pharma Limited' on March 20, 2019. The Company incorporated in March, 2003 by Mr. Hemant Bhagat and Late.
Shree Chandravadan Bhagat.
On April 1, 2003, the Company acquired the going concern business of M/s.
Chandra Bhagat Corporation, partnership firm along with all its assets and liabilities.

About Infinium Pharmachem Ltd

Infinium Pharmachem Limited was originally incorporated as 'Infinium Pharmachem Private Limited' on November 21, 2003 issued by the Registrar of Companies, Gujarat.
Later on, Company converted its status into Public Company and the name of Company was changed to 'Infinium Pharmachem Limited' vide fresh Certificate of Incorporation dated August 12, 2022.
Company is engaged in manufacturing and selling of Iodian based Pharmaceutical Intermediates.
The Company has its manufacturing plant at Dist.
Anand, Gujarat, since inception. The Company's manufacturing capabilities and technical expertise have catered industries such as Pharmaceutical & Biotech, Specialty & Performance Chemicals, Agrochemicals, Human Health, Animal Health, Cosmetics, Sanitation, Electrical, Electronics, etc.

FAQs for the comparison of Chandra Bhagat Pharma Ltd and Infinium Pharmachem Ltd

Which company has a larger market capitalization, Chandra Bhagat Pharma Ltd or Infinium Pharmachem Ltd?

Market cap of Chandra Bhagat Pharma Ltd is 24 Cr while Market cap of Infinium Pharmachem Ltd is 327 Cr

What are the key factors driving the stock performance of Chandra Bhagat Pharma Ltd and Infinium Pharmachem Ltd?

The stock performance of Chandra Bhagat Pharma Ltd and Infinium Pharmachem Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Chandra Bhagat Pharma Ltd and Infinium Pharmachem Ltd?

As of May 5, 2026, the Chandra Bhagat Pharma Ltd stock price is INR ₹33.0. On the other hand, Infinium Pharmachem Ltd stock price is INR ₹210.2.

How do dividend payouts of Chandra Bhagat Pharma Ltd and Infinium Pharmachem Ltd compare?

To compare the dividend payouts of Chandra Bhagat Pharma Ltd and Infinium Pharmachem Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.